These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27000027)

  • 1. Zero-Order Controlled Delivery of Gliclazide from Polyethylene Oxides Matrix Tables: In vitro and In vivo Evaluation.
    Wang L; Yang X; Di Y; Chen K; Wen H; Pan W
    Curr Drug Deliv; 2017; 14(1):136-144. PubMed ID: 27000027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Evaluation of Hydrophilic Matrix System Containing Polyethylene Oxides for the Zero-Order Controlled Delivery of Water-Insoluble Drugs.
    Wang L; Chen K; Wen H; Ouyang D; Li X; Gao Y; Pan W; Yang X
    AAPS PharmSciTech; 2017 Jan; 18(1):82-92. PubMed ID: 26883263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluation of controlled-release matrix tablets of highly water-soluble drug applying different mw polyethylene oxides (PEO) as retardants.
    Wen H; Li X; Li Y; Wang H; Wang Y; Wang T; Pan W; Yang X
    Drug Dev Ind Pharm; 2018 Apr; 44(4):544-552. PubMed ID: 29130753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system.
    Yang Y; Zhao Z; Wang Y; Yang L; Liu D; Yang X; Pan W
    Int J Pharm; 2016 Jun; 506(1-2):340-50. PubMed ID: 27132166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of two hydrophobic polymers on the release of gliclazide from their matrix tablets.
    Hussain T; Saeed T; Mumtaz AM; Javaid Z; Abbas K; Awais A; Idrees HA
    Acta Pol Pharm; 2013; 70(4):749-57. PubMed ID: 23923399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical availability of gliclazide from selected matrix formulation tablets.
    Hermann TW; Dobrucki R; Piechocki S; Resztak M; Reh R
    Med Sci Monit; 2005 Jun; 11(6):BR181-188. PubMed ID: 15917713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro evaluation of a solid dispersion system of gliclazide:PEG 6000.
    Asyarie S; Rachmawati H
    PDA J Pharm Sci Technol; 2007; 61(5):400-10. PubMed ID: 18047178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet.
    Qin C; He W; Zhu C; Wu M; Jin Z; Zhang Q; Wang G; Yin L
    Int J Pharm; 2014 May; 466(1-2):276-85. PubMed ID: 24607209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion.
    Khattab IS; Nada A; Zaghloul AA
    Drug Dev Ind Pharm; 2010 Aug; 36(8):893-902. PubMed ID: 20196643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
    Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
    J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix tablets for sustained release of repaglinide: Preparation, pharmacokinetics and hypoglycemic activity in beagle dogs.
    He W; Wu M; Huang S; Yin L
    Int J Pharm; 2015 Jan; 478(1):297-307. PubMed ID: 25434592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and in vitro evaluation of gliclazide sustained-release matrix pellets: formulation and storage stability.
    Wang L; Wang J; Lin X; Tang X
    Drug Dev Ind Pharm; 2010 Jul; 36(7):814-22. PubMed ID: 20345281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of poly(ethylene oxide) in controlled release tablet systems: a review.
    Ma L; Deng L; Chen J
    Drug Dev Ind Pharm; 2014 Jul; 40(7):845-51. PubMed ID: 24001212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluation of gliclazide push-pull osmotic pump coated with aqueous colloidal polymer dispersions.
    Tang X; Tai LY; Yang XG; Chen F; Xu HM; Pan WS
    Drug Dev Ind Pharm; 2013 Jan; 39(1):67-76. PubMed ID: 22339718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release.
    Gong L; Sun Y; Yu M; Gao Y; Zou M; Cheng G
    AAPS PharmSciTech; 2018 Oct; 19(7):3277-3286. PubMed ID: 30215168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide.
    Hong SS; Lee SH; Lee YJ; Chung SJ; Lee MH; Shim CK
    J Control Release; 1998 Feb; 51(2-3):185-92. PubMed ID: 9685916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer)-dispersed sustained-release tablet for imperialine to simultaneously prolong the drug release and improve the oral bioavailability.
    Lin Q; Fu Y; Li J; Qu M; Deng L; Gong T; Zhang Z
    Eur J Pharm Sci; 2015 Nov; 79():44-52. PubMed ID: 26349052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs.
    Zhang X; Yi Y; Qi J; Lu Y; Tian Z; Xie Y; Yuan H; Wu W
    Int J Pharm; 2013 Aug; 452(1-2):233-40. PubMed ID: 23688622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of extended zero-order release gliclazide tablets by central composite design.
    Vijayalakshmi P; Devi VK; Narendra C; Srinagesh S
    Drug Dev Ind Pharm; 2008 Jan; 34(1):33-45. PubMed ID: 18214753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling of systemic absorption of gliclazide through incorporation into alginate beads.
    Al-Kassas RS; Al-Gohary OM; Al-Faadhel MM
    Int J Pharm; 2007 Aug; 341(1-2):230-7. PubMed ID: 17507189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.